MicroRNA-34a通过多向调控促癌基因抑制肾癌细胞生长

目的:探讨microRNA-34a(miR-34a)在肾癌细胞中的生物学作用及调控机制.方法:应用miR-34amimics在体外转染769P,786-O和Caki-1细胞;运用qRT-PCR检测miR-34a在三个细胞株的相对表达情况,以及转染后癌基因mRNA的表达情况;观察miR-34a对细胞生长的影响.结果:769P,786-O和Caki-1细胞中miR-34a在786-O中表达最低,769P次之,Caki-1表达最高;利用miR-34a mimics升高769P,786-O和Caki-1细胞miR-34a,发现三个细胞株多个癌基因mRNA表达不同程度的降低(P＜0.05)及生长和集聚能力的降低.结论:miR-34a可能通过调控多个癌基因表达在肾癌中起抑癌作用.miR-34a mimics可抑制肾癌细胞的生长,因此miR-34a有可能作为肾癌基因治疗的新靶点.     

Let-7a下调k-Ras和c-Myc癌基因的表达抑制肾癌细胞增殖

目的：MicroRNA 是近年发现的一类单链小分子RNA,对它的研究已成为一个新的热点。最近的研究发现,1et-7a 在细胞内影响着基因的表达调控,在疾病发生中起着及极重要的作用,尤其是在肿瘤的发展过程中,let-7a扮演着不可替代的角色。本文主要研究let-7a 在肾癌细胞株中的表达情况及其调控的靶基因、抑制细胞增殖的机制,对探索肾癌的致病基因,寻求肾癌新的治疗途径有重要意义。方法：应用化学合成的let-7a 模拟物（mimics）用脂质体Lipofectamine 2000 在体外瞬时转染786-O 和Caki-1肾癌细胞株,转染48 小时后采用荧光定量RT-PCR的方法检测let-7a 及c-Myc、k-Ras mRNA的表达情况,Western blot 检测这两株肾癌细胞转染了let-7a mimics 后c-Myc 及k-Ras 蛋白的表达变化;转染let-7a mimics 后分别在24、48、72 小时三个时间点用CCK-8 试剂盒检测对肾癌细胞株增殖的影响。结果：786-O 和Caki-1 肾癌细胞株中let-7a 的表达量明显低于正常肾小管上皮细胞株HK-2（P〈0.05）; 转染了let-7amimics的786-O 和Caki-1 肾癌细胞株,RT-PCR 及Western blot 结果显示c-Myc、k-Ras 在基因及蛋白的表达水平明显下调（P〈0.05）;CCK-8 检测结果显示转染了let-7a mimics的肾癌细胞株细胞增殖能力明显明显受到抑制,与阴性对照组比较差异有统计学意义（P〈0.05）。结论：Let-7a 在在肿瘤细胞与正常细胞中存在明显差异,let-7a 通过调控c-Myc、k-Ras的表达能抑制肾癌细胞增殖。Let-7a mimics 可以抑制肾癌细胞的增殖,因此上调Let-7a 的表达有可能成为肾癌基因治疗的一种有效治疗手段。     

Let-7a 下调 k-Ras 和 c-Myc 癌基因的表达抑制肾癌细胞增殖

摘要 目的： MicroRNA 是近年发现的一类单链小分子 RNA, 对它的研究已成为一个新的热点。最近的研究发现, 1et-7a 在细胞内 影响着基因的表达调控,在疾病发生中起着及极重要的作用, 尤其是在肿瘤的发展过程中, let-7a 扮演着不可替代的角色。本文主 要研究 let-7a 在肾癌细胞株中的表达情况及其调控的靶基因、 抑制细胞增殖的机制,对探索肾癌的致病基因, 寻求肾癌新的治疗 途径有重要意义。 方法： 应用化学合成的 let-7a 拟物（ mimics ）用脂质体 Lipofectamine 2000 在体外瞬时转染 786-O 和 Caki-1 肾 癌细胞株, 转染 48 小时后采用荧光定量 RT-PCR 的方法检测 let-7a 及 c-Myc、 k-Ras mRNA 的表达情况, Western blot 检测这两株 肾癌细胞转染了 let-7a mimics 后 c-Myc 及 k-Ras 蛋白的表达变化;转染 let-7a mimics 后分别在 24、 48、 72 小时三个时间点用 CCK-8 试剂盒检测对肾癌细胞株增殖的影响。 结果： 786-O 和 Caki-1 肾癌细胞株中 let-7a 的表达量明显低于正常肾小管上皮细胞 株 HK-2 （P<0.05 ） ; 转染了 let-7amimics 的 786-O 和 Caki-1 肾癌细胞株, RT-PCR 及 Western blot 结果显示 c-Myc、 k-Ras 在基因及 蛋白的表达水平明显下调 （P<0.05 ） ; CCK-8 检测结果显示转染了 let-7a mimics 的肾癌细胞株细胞增殖能力明显明显受到抑制, 与 阴性对照组比较差异有统计学意义 （P<0.05 ）。结论： Let-7a 在在肿瘤细胞与正常细胞中存在明显差异, let-7a 通过调控 c-Myc、 k-Ras 的表达能抑制肾癌细胞增殖。 Let-7a mimics 可以抑制肾癌细胞的增殖,因此上调 Let-7a 的表达有可能成为肾癌基因治疗的 一种有效治疗手段。     

肾癌中hepaCAM外显子2异常甲基化与hepCAM表达的关系

探讨肾癌中抑癌基因肝细胞粘附分子hepaCAM表达与hepaCAM外显子2 CpG岛甲基化状态的关系。采用甲基化敏感性限制性内切酶PCR、RT-PCR法检测肾癌细胞株(786-0,RC-2)和43例肾癌及相应的癌旁组织中hepaCAM外显子2的甲基化状态及hepaCAM mRNA的表达。786-0细胞hepaCAM表达水平低于RC-2细胞(P0.05);786-0和RC-2细胞,前者存在hepaCAM外显子2甲基化,后者未检测到。肾癌组织中hepaCAM mRNA表达水平显著低于癌旁组织(P0.001);肾癌组织hepaCAM外显子2的甲基化率为34.9%,癌旁组织2.33%,两者差异有显著意义(P0.001),但在临床病理参数中的差异无统计学意义(P0.05)。hepaCAM外显子2甲基化的肾癌组织其mRNA的表达水平显著低于未甲基化的肾癌组织(P0.05)。因此,肾癌hepaCAM外显子2的甲基化可能是导致hepaCAM表达下降或缺失的原因之一,hepaCAM甲基化的研究为探讨肾癌发生发展的机制提供了新的理论依据。     

hepaCAM和VEGF基因表达与肾透明细胞癌侵袭转移关系的探讨

研究肾癌细胞株786-0,RC-2及肾透明细胞癌组织中肝细胞黏附分子(hepatocyte cell adhesion molecule,hepaC-AM)和血管内皮生长因子(VEGF)mRNA表达及其与肾透明细胞癌侵袭转移的关系。应用逆转录聚合酶链反应(RT-PCR)检测786-0、RC-2、正常肾组织hepaCAM和VEGFmRNA表达,73例肾透明细胞癌组织及相应癌旁组织中hepaCAMmRNA表达,43例肾透明细胞癌组织及相应癌旁组织VEGFmRNA表达,并比较它们之间的差异性和相关性。与正常肾组织比较786-0,RC-2的hepaCAMmRNA显著降低(P0.05);VEGFmRNA显著升高(P0.05)。肾透明细胞癌组织hepaCAMmRNA显著低于癌旁组织(P0.05);VEGFmRNA显著高于癌旁组织(P0.05)。在肾透明细胞癌组织中临床Ⅰ+Ⅱ期和Ⅲ+Ⅳ期两组VEGFmRNA表达差异具有统计学意义(P0.05),hepaCAM与VEGFmRNA呈负相关(r=-0.329,P0.05)。提示hepaC-AM基因缺失可能参与肾透明细胞癌侵袭转移,其机制可能与调节VFGF表达改变有关,hepaCAM有望成为一种新的肾癌基因治疗的靶分子。     

抑癌基因NPRL2对肾癌786-O细胞增殖和凋亡的影响

抑癌基因NPRL2(nitrogen permease regulator-like 2)在人类许多正常组织中均有明显的表达,而在人类多种肿瘤组织中的表达明显降低。该实验通过构建重组质粒pEGFP-N1-NPRL2并转染肾癌786-O细胞株,应用倒置荧光显微镜、RT-PCR和Western blot检测NPRL2基因的表达情况;MTT法检测786-O细胞增殖的情况;流式细胞仪分析细胞周期和细胞凋亡情况。结果显示:肾癌786-O细胞株转染重组质粒pEGFP-N1-NPRL2后,通过荧光显微镜可以观察到绿色荧光;RT-PCR和Western blot检测到NPRL2基因的转录和蛋白质表达水平明显增加(P<0.05);MTT法检测发现72 h时pEGFP-N1-NPRL2组、pEGFP-N1组和空白对照组的细胞D490值分别为0.654±0.030、1.528±0.022和1.572±0.036,pEGFP-N1-NPRL2组细胞的增殖较其他两组受到明显的抑制(P<0.05);流式细胞仪检测显示pEGFP-N1-NPRL2组、pEGFP-N1组和空白对照组的凋亡率分别为18.82%±0.40%、5.65%±0.12%和5.85%±0.07%,而处于G0/G1期的细胞比例分别为69.80%±1.40%、46.24%±1.30%和47.03%±0.45%,与其他两组相比,pEGFP-N1-NPRL2组的凋亡率显著增高而且G0/G1期细胞明显增多,表现出G0/G1期阻滞。提示抑癌基因NPRL2的转染可以抑制786-O细胞的增殖,并诱导其凋亡将细胞周期阻滞于G0/G1期。     

miRNA-145-5p调控FMNL2基因对口腔鳞癌干细胞增殖、迁移的影响

摘要 目的：分析miRNA-145-5p调控形成素2（formin-like 2,FMNL2）基因对口腔鳞癌干细胞增殖、迁移的影响。方法：按照脂质体2000说明书对细胞进行转染miRNA-145-5p inhibitor及miRNA-145-5p mimics,按照实验设计,将其分为空白组、沉默组（miRNA-145-5p inhibitor）及过表达组（miRNA-145-5p mimics）。荧光定量PCR法检测miRNA-145-5p、FMNL2表达量,MTT检测细胞增殖能力,流式细胞仪检测细胞凋亡能力,细胞划痕实验检测细胞迁移能力,采用Western blot法检测各组细胞中Wnt/β-catenin信号通路蛋白表达量。结果：过表达组miRNA-145-5p、Bax蛋白表达量,凋亡率,细胞G0/G1比例高于沉默组,具有统计学差异（P＜0.05）;过表达组口腔鳞癌干细胞增殖率,FMNL2表达量、MMP-13、β-catenin、Bcl-2、APC蛋白表达量低于沉默组,具有统计学差异（P＜0.05）;过表达组口腔鳞癌干细胞迁移能力弱于沉默组,具有统计学差异（P＜0.05）。结论：miRNA-145-5p通过靶向调控FMNL2,作用于Wnt/β-catenin信号通路调控口腔鳞癌干细胞,进而抑制细胞增殖、迁移。     

Spautin-1通过抑制自噬可增强舒尼替尼诱导的肾癌细胞凋亡

目的:研究spautin-1(一种自噬抑制剂)是否能抑制舒尼替尼诱导的肾癌细胞的自噬以及对舒尼替尼诱导的肾癌细胞凋亡的影响。方法:以肾癌细胞系786-O细胞为模型,Western Blot检测spautin-1对舒尼替尼诱导786-O细胞自噬的影响;Cell Counting Kit-8(CCK-8)检测spautin-1和舒尼替尼对786-O细胞增殖的影响;应用流式细胞术,检测spautin-1对舒尼替尼诱导的786-O细胞凋亡的影响;Western Blot检测spautin-1的促凋亡作用与PI3K/AKT/GSK3β信号通路及抗凋亡蛋白Bcl-2和Mcl-1的关系。结果:与舒尼替尼单独处理组相比,spautin-1能通过降低Beclin-1的表达显著抑制舒尼替尼在786-O细胞中诱导的自噬;Spautin-1和舒尼替尼联合作用明显增强舒尼替尼对786-O细胞增殖的抑制作用;Spautin-1能进一步增强舒尼替尼诱导的786-O细胞的凋亡;Spautin-1和舒尼替尼联合处理786-O细胞时,可以显著降低p-AKTSer473和p-GSK3βSer9的蛋白表达水平,增强GSK3β的活性,进而下调Bcl-2、Mcl-1的表达。结论:Spautin-1能通过抑制AKT活性并活化GSK3β,进一步降低抗凋亡蛋白Bcl-2、Mcl-1的表达,增强舒尼替尼诱导的肾癌细胞凋亡。     

RNA干扰Ezrin体外对肾癌细胞株786-0增殖、凋亡的影响(英文)

目的:构建膜-细胞骨架联接蛋白Ezrin基因特异性短发卡RAN表达载体(small hairpin RNA,shRNA),探讨其对肾癌细胞株786-0细胞凋亡、增殖的影响。方法:以Ezrin为靶基因,以Pgenesil-1质粒为载体,设计和构建重组体,设计2条发夹式RNA(shRNA),合成后克隆入载体Pgenesil-1,扩增并中量提取质粒,应用脂质体Lipofectamine 2000转染进786-0细胞,重组质粒转染786-0肾癌细胞株,用运实时荧光定量PCR进行筛选鉴定,筛选出抑制率较高的重组质粒载体shRNA-Ezrin1,用shRNA-Ezrin1转染786-0细胞,采用MTT、流式细胞仪、电镜检测,观察RNA干扰Ezrin后肾癌细胞株786-0细胞增殖能力的改变。结果:shRNA干扰后786-0细胞增殖活性减弱,G0/G1时段明显延长(P0.01),PI缩短(P0.01),细胞凋亡率增加(P0.01)。结论:Ezrin与肾癌细胞凋亡、增殖有关,有望成为肾癌基因治疗的一个新靶点。     

白藜芦醇经PI3K/Akt/mTOR 信号通路诱导人肾癌786-O细胞自噬

白藜芦醇(resveratrol)可抑制人肾癌786-O细胞增殖,并诱导其凋亡,但是白藜芦醇对786-O细胞自噬(autophagy)的影响及机制尚不清楚。为探究其机制,体外培养786-O细胞,采用CCK-8检测786-O细胞活力;TUNEL染色检测786-O细胞凋亡;透射电子显微镜观察786-O细胞自噬体;吖啶橙染色观察786-O细胞自噬小泡;GFP-LC3质粒转染分析观察786-O细胞自噬体;Western印迹检测LC3、beclin-1、PI3K、p-PI3K、Akt、p-Akt、mTOR和p-mTOR的表达。结果显示,白藜芦醇以浓度和时间依赖性的方式抑制786-O细胞活力,并诱导细胞凋亡;与对照组相比,白藜芦醇使786-O细胞自噬增强;Western印迹结果显示,与对照组相比,白藜芦醇组LC3-II/LC3-I和Beclin-1显著增高(P0.01),表明白藜芦醇导致786-O细胞自噬体积累。与对照组相比,白藜芦醇使786-O细胞的p-PI3K/PI3K,p-Akt/Akt和p-mTOR/mTOR显著降低(P0.01),表明白藜芦醇可通过PI3K/Akt/mTOR信号通路增强自噬。综上所述,白藜芦醇通过抑制PI3K/Akt/mTOR信号通路从而诱导786-O细胞自噬。     

LINC00961 restrains cancer progression via modulating epithelial–mesenchymal transition in renal cell carcinoma

Recently, long noncoding RNA have been identified as new gene regulators and prognostic biomarkers in various cancers, including renal cell carcinoma (RCC). The expression and biological roles of LINC00961 have been reported in many human cancers. However, up to date, no study of LINC00961 has been shown in RCC. Currently, we aimed to investigate the function of LINC00961 in RCC progression. Interestingly, we observed that LINC00961 could act as a novel biomarker in predicting the diagnosis of RCC. Then, we found that LINC00961 was greatly downregulated in RCC cell lines (Caki-1, Caki-2, 786-O, A498, and ACHN cells) compared with normal renal cell lines (HK-2 cells). Then, 786-O cells and ACHN cells were infected with LV-LINC00961. As displayed in our current study, LINC00961 overexpression could obviously suppress the proliferation and survival of RCC cells in vitro. In addition, RCC cell apoptosis was greatly induced and cell cycle progression was blocked in G1 phase by upregulation of LINC00961 in 786-O cells and ACHN cells. Subsequently, we found that LV-LINC00961 was able to restrain RCC cell migration and cell invasion capacity. Meanwhile, the messenger RNA and protein expression levels of epithelial–mesenchymal transition (EMT)-associated markers Slug and N-cadherin in RCC cell lines were dramatically inhibited by overexpressing LINC00961. Finally, the in vivo experiment was carried out and we observed that LINC00961 could inhibit RCC development through modulating EMT process. Taken these together, it was indicated in our study that LINC00961 was involved in RCC progression through targeting EMT pathway.     

Effects of homocysteine and its related compounds on oxygen consumption of the rat heart tissue homogenate: the role of different gasotransmitters

Accumulating evidence indicates that microRNAs are implicated in tumor initiation and progression through negatively regulating oncogenes or tumor suppressor genes. In the present study, we report that the expression of miR-200a was significantly lower in renal cell carcinoma (RCC) specimens and RCC cell lines. Restoration of miR-200a suppressed cell growth, arrested cell cycle progression, and promoted cell apoptosis in RCC cell lines. We next used qRT-PCR array technology to identify Sirtuin 1 (SIRT1) as one of the downregulated proteins during miR-200a overexpression in 786-O cells. Following a further assay by luciferase reporter system, SIRT1 was validated as a direct target of miR-200a. Moreover, siRNA-mediated knockdown of SIRT1 could partially phenocopy the effects of miR-200a overexpression. In contrast, overexpression of truncated SIRT1 (without an endogenous 3′-UTR) could rescue the effect of miR-200a overexpression on 786-O cells, which suggested that SIRT1 3′-UTR is targeted by miR-200a specifically. These observations provide further evidence for a critical tumor-suppressive role of the miR-200a in RCC in addition to identifying a novel regulatory mechanism, which may contribute to SIRT1 upregulation in RCC.     

Timosaponin AIII inhibits metastasis of renal carcinoma cells through suppressing cathepsin C expression by AKT/miR-129-5p axis

Timosaponin AIII (TSAIII) is a steroidal saponin that exerts anticancer activity on various cancer cells. In this study, we explore the effects of TSAIII on renal cell carcinoma (RCC) cells. Our findings show that TSAIII treatment (<8 μM) insignificantly influenced cell viability and cell cycle distribution of human RCC cell lines 786-O, A-498, and ACHN. Further observations revealed that TSAIII inhibited migration and invasion of 786-O and A-498 cells, as well as significantly decreased the production and expression of cathepsin C (CTSC) in both the cell types. Kinase cascade analysis exhibited that PI3K/AKT activation was inhibited, but PTEN expression was increased, in response to TSAIII treatments. Combining TSAIII and PI3K inhibitors, LY294002 synergically reduced the migration and invasion of 786-O and A-498 cells, as well as decreased the CTSC expression in both the cell types. We also observed that miR-129-5p bound to CTSC gene and suppressed the expression of CTSC and demonstrated that the miR-129-5p expression was synergically enhanced by TSAIII and LY294002. In addition, pretreatment with antago-miR-129-5p significantly restored the CTSC expression and the migration and invasion of TSAIII-treated 786-O cells. In conclusion, our findings reveal that TSAIII inhibits the metastatic properties of RCC cells, contributing to the inhibition of PI3K/AKT and the increase of miR-129-5p and the subsequent downregulation of CTSC. This suggests that TSAIII has significant antimetastatic activity against RCC cells and may be beneficial to RCC treatments.     

β-Ionone represses renal cell carcinoma progression through activating LKB1/AMPK-triggered autophagy

β-Ionone, the end ring analog of β-carotenoids, has been proven to have an antitumor effect in a variety of cancers. In this study, we investigated the impact of β-ionone on renal cell carcinoma (RCC) cell lines (786-O and ACHN) using colony formation assays, flow cytometry analysis, and western blot analysis. We found that β-ionone effectively inhibited the proliferation of RCC cells in vitro, which was also confirmed in a xenograft model. Moreover, we found that β-ionone could induce autophagy, as indicated by LC3 puncta in 786-O and ACHN cell lines and the expression of LC3 in β-ionone-treated RCC cells. To further explore the underlying mechanism, we assessed liver kinase B1/AMP-activated protein kinase (LKB1/AMPK) signaling pathway activity, and the results showed that β-ionone inhibited the proliferation of RCC cells by inducing autophagy via the LKB1/AMPK signaling pathway. In summary, our findings provide a new therapeutic strategy of β-ionone-induced autophagy in RCC.     

Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma

The orphan nuclear receptor NR4A1 exhibits pro-oncogenic activity in cancer cell lines. NR4A1 activates mTOR signaling, regulates genes such as thioredoxin domain containing 5 and isocitrate dehydrogenase 1 that maintain low oxidative stress, and coactivates specificity protein 1 (Sp1)-regulated pro-survival and growth promoting genes. Transfection of renal cell carcinoma (RCC) ACHN and 786-O cells with oligonucleotides that target NR4A1 results in a 40–60% decrease in cell proliferation and induction of apoptosis. Moreover, knockdown of NR4A1 in RCC cells decreased bcl-2, survivin and epidermal growth factor receptor expression, inhibited of mTOR signaling, induced oxidative and endoplasmic reticulum stress, and decreased TXNDC5 and IDH1. We have recently demonstrated that selected 1,1-bis(3''-indolyl)-1-(p-substituted phenyl)methane (C-DIM) compounds including the p-hydroxyphenyl (DIM-C-pPhOH) and p-carboxymethyl (DIM-C-pPhCO₂Me) analogs bind NR4A1 and act as antagonists. Both DIM-C-pPhOH and DIM-C-pPhCO₂Me inhibited growth and induced apoptosis in ACHN and 786-O cells, and the functional and genomic effects of the NR4A1 antagonists were comparable to those observed after NR4A1 knockdown. These results indicate that NR4A1 antagonists target multiple growth promoting and pro-survival pathways in RCC cells and in tumors (xenograft) and represent a novel chemotherapy for treating RCC.     

RUNX3 mediates suppression of tumor growth and metastasis of human CCRCC by regulating cyclin related proteins and TIMP-1

Here we presented that the expression of RUNX3 was significantly decreased in 75 cases of clear cell renal cell carcinoma (CCRCC) tissues (p<0.05). Enforced RUNX3 expression mediated 786-O cells to exhibit inhibition of growth, G1 cell-cycle arrest and metastasis in vitro, and to lost tumorigenicity in nude mouse model in vivo. RUNX3-induced growth suppression was found partially to regulate various proteins, including inhibition of cyclinD1, cyclinE, cdk2, cdk4 and p-Rb, but increase of p27(Kip1), Rb and TIMP-1. Therefore, RUNX3 had the function of inhibiting the proliferative and metastatic abilities of CCRCC cells by regulating cyclins and TIMP1.     

Identification of TGF-β-activated kinase 1 as a possible novel target for renal cell carcinoma intervention

Renal cell carcinoma (RCC) is common renal malignancy within poor prognosis. TGF-β-activated kinase 1 (TAK1) plays vital roles in cell survival, apoptosis-resistance and carcinogenesis through regulating nuclear factor-κB (NF-κB) and other cancer-related pathways. Here we found that TAK1 inhibitors (LYTAK1, 5Z-7-oxozeanol (5Z) and NG-25) suppressed NF-κB activation and RCC cell (786-O and A489 lines) survival. TAK1 inhibitors induced apoptotic cytotoxicity against RCC cells, which was largely inhibited by the broad or specific caspase inhibitors. Further, shRNA-mediated partial depletion of TAK1 reduced 786-O cell viability whiling activating apoptosis. Significantly, TAK1 was over-expressed in human RCC tissues, and its level was correlated with phosphorylated NF-κB. Finally, kinase inhibition or genetic depletion of TAK1 enhanced the activity of vinblastine sulfate (VLB) in RCC cells. Together, these results suggest that TAK1 may be an important oncogene or an effective target for RCC intervention.     

Calcium-activated nucleotidase 1 silencing inhibits proliferation,migration, and invasion in human clear cell renal cell carcinoma

Calcium-activated nucleotidase 1 (CANT1, belongs to the apyrase family, is widely expressed in various organs. However, the biological function of CANT1 remains poorly explored. In this study, we aimed to investigate the expression profile and functions of CANT1 in clear cell renal cell carcinoma (ccRCC). Our data show that the protein level of CANT1 was significantly higher in tumor tissues than in adjacent normal tissues. CANT1 silencing suppressed cell proliferation, migration, and invasion obviously in 769-P and 786-O cells, arrested cell cycle in S phase and promoted apoptosis in 769-P cells. In conclusion, the present study shows the different expression mode of CANT1 in human ccRCC tumor tissue and adjacent normal tissue, denotes the function of CANT1 in ccRCC cells and provides potential molecular mechanisms and pathways of CANT1 antitumor function in ccRCC.     

Anti-tumor effects of fusion vaccine prepared by renal cell carcinoma 786-O cell line and peripheral blood dendritic cells of healthy volunteers in vitro and in human immune reconstituted SCID mice

Dendritic cells (DC), as professional antigen presenting cells, play the central role in the process of body initiating the anti-tumor immunity, and the study on DC anti-tumor vaccine has become heated in recent years. In this study, we used polyethylene glycol (PEG) to induce renal cell carcinoma (RCC) 786-O cell line fused with peripheral blood DC of healthy volunteers, and discuss the biological characteristics of fusion vaccine and its anti-tumor effects in vitro and in human immune reconstituted SCID mice model of RCC. The study found that PEG could effectively induce cell fusion, and the expressions of CD86 and HLA-DR in fusion vaccine group were significantly up-regulated compared with the DC control group; the secretion of IL-12 was much higher and longer than that of the control; the functions of dendritic cell-tumor fusion vaccine to stimulate the proliferation of allogenic T lymphocytes and to kill RCC786-O cells in vitro were significantly higher than those of the control group, and after the killing, apoptosis body was observed in the target cells; after the injection of fusion vaccine into human immune reconstituted SCID mice model of RCC786-O via vena caudalis, the volume of mice tumor was reduced significantly, proliferation index of tumor cells decreased obviously compared with that of the control group, and more hemorrhage and putrescence focuses presented, accompanying large quantity of lymphocytes soakage. The results of this experimental study shows that fusion vaccine of RCC786-O cell line and DC can significantly stimulate the proliferation of allogenic T cells and specifically inhibit and kill RCC cells in vitro and in vivo, which makes the DC-RCC786-O fusion vaccine a possible new way of effective RCC immunotherapy.